Skip to content

Trial Summary

Prevalence and clinical outcomes of KRASG12C mutated advanced lung cancer patients in Australia


ACTRN/NCT /ethics:

Scientific title:

Sponsor / Cooperative group:

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeObservational
Age Range-
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Phone08 8222 6410
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting